Invesco Pharmaceuticals ETF (NYSEARCA:PJP) Short Interest Update

Invesco Pharmaceuticals ETF (NYSEARCA:PJP) was the target of a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 52,162 shares, a growth of 326.1% from the June 30th total of 12,241 shares. Currently, 1.4% of the company’s stock are sold short. Based on an average daily trading volume, of 76,346 shares, the days-to-cover ratio is currently 0.7 days.

Invesco Pharmaceuticals ETF Price Performance

NYSEARCA:PJP opened at $120.60 on Tuesday. The firm’s 50-day moving average price is $114.51 and its 200-day moving average price is $108.70. The company has a market capitalization of $438.98 million, a PE ratio of 15.59 and a beta of 0.45. Invesco Pharmaceuticals ETF has a 1-year low of $80.63 and a 1-year high of $122.69.

Institutional Investors Weigh In On Invesco Pharmaceuticals ETF

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp increased its stake in shares of Invesco Pharmaceuticals ETF by 11.6% during the first quarter. Jones Financial Companies Lllp now owns 2,428 shares of the company’s stock valued at $210,000 after purchasing an additional 252 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Invesco Pharmaceuticals ETF in the 2nd quarter worth approximately $799,000. Tower Research Capital LLC TRC boosted its position in shares of Invesco Pharmaceuticals ETF by 102.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,680 shares of the company’s stock worth $374,000 after purchasing an additional 2,374 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Invesco Pharmaceuticals ETF by 214.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 12,236 shares of the company’s stock worth $1,114,000 after buying an additional 8,344 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of Invesco Pharmaceuticals ETF in the 3rd quarter worth approximately $504,000.

Invesco Pharmaceuticals ETF Company Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types.